Alpha Lifetech Inc. was founded by a group of scientists with extensive experience in membrane protein production, nanobody discovery, monoclonal development, and other pharmaceutical pre-development services. Based on our several technology service platforms, Alpha Lifetech Inc. has launched nearly 10,000 high-quality spot membrane protein reagents, cytokines, drug target antibodies and other related reagents. Whether you're working in the fields of immunology, cell biology, molecular biology, or any other scientific discipline, Alpha Lifetech's comprehensive range of research products will help you achieve accurate and reliable results. We pride ourselves on being able to offer a comprehensive set of high-quality products and services tailored to customer needs, which help advance the projects of scientific research institutions, academics, and enterprises in the life science industry.
Alpha Lifetech Inc. is committed to providing the highest level of customer services, competitive pricing, speedy delivery, and a comprehensive, cutting-edge product offering. Our sales and technical support staff are available to help you select the right products and service solutions. As a reliable supplier and partner, Alpha Lifetech Inc. always puts customers first. We cherish every opportunity to collaborate with worldwide customers in scientific exploration. Welcome to contact our technical support at any time.
Our team of experienced scientists works closely with customers to design and execute tailored strategies for nanobody discovery, ensuring the generation of high-quality leads that align with project goals.
Antibody humanization from a broad range of parental species including mouse, rat, rabbit, llama, and avian.
Our Membrane Proteomics platform offers a comprehensive solution for the identification, quantification, and characterization of membrane proteins, providing valuable insights into their functions and interactions within the cell.
Alpha Lifetech can offer the native antibody libraries (scFv, Fab, VHH Formats and customized) from host animals like Goat, Camel and Llama.
Llamas (Lama glama) and other camelids naturally produce a unique class of antibodies — heavy-chain-only antibodies (HCAbs) — whose variable domains (VHH) are the smallest known antigen-binding fragments in nature. At just 12–15 kDa, these single-domain nanobodies exhibit extraordinary stability, deep epitope penetration, and ease of engineering, making llama immunization the preferred route for next-generation therapeutic and diagnostic nanobody development.
Successful nanobody design begins with a precisely controlled llama immunization protocol. Antigens — recombinant proteins, peptides, membrane proteins, or whole cells — are administered over 4–6 weeks using adjuvant-optimized schedules. Peripheral blood lymphocytes are then harvested to construct a high-diversity VHH phage display library, which serves as the foundation for downstream screening and selection of high-affinity nanobody candidates.
The quality of nanobodies generated is directly tied to antigen design. For membrane protein targets, detergent-solubilized or nanodisc-reconstituted preparations are preferred. For conformational epitopes, native-fold antigens are critical. Alpha Lifetech's antigen engineering team provides end-to-end support — from gene synthesis and protein expression to quality validation — ensuring optimal immunogen presentation for maximum immune response in llama hosts.
Post-immunization, VHH gene repertoires are amplified by RT-PCR from total RNA of B-lymphocytes. Diversity is a critical metric: libraries of 108–1010 unique clones are constructed using phage or yeast display platforms. Alpha Lifetech's proprietary library construction protocols maximize CDR3 diversity — the primary determinant of antigen specificity — yielding nanobody pools with exceptional coverage of the antigenic landscape.
Multiple rounds of biopanning or FACS-based sorting identify lead nanobody candidates with picomolar affinity. Hits are characterized by ELISA, SPR, and BLI for kinetic profiling. Affinity maturation via error-prone PCR or CDR-targeted mutagenesis further enhances binding performance. The final candidates are expressed in E. coli or yeast, purified to homogeneity, and validated for functional activity in target-relevant assays.
The global nanobody/VHH antibody market was valued at over USD 1.2 billion in 2023 and is projected to exceed USD 5 billion by 2032, growing at a CAGR of ~17%. Pharmaceutical companies, diagnostic kit manufacturers, and CROs are all investing heavily in llama immunization-based nanobody pipelines as a cost-effective alternative to conventional monoclonal antibody development.
The approval of caplacizumab (Cablivi®) — the first nanobody-based therapeutic — by the FDA and EMA has validated the clinical potential of llama-derived VHH antibodies. Over 50 nanobody candidates are currently in clinical trials for oncology, inflammation, infectious disease, and CNS disorders, signaling a paradigm shift in biologic drug development.
Nanobodies' small size, high stability, and ease of site-specific conjugation make them ideal building blocks for lateral flow assays, ELISA kits, electrochemical biosensors, and microfluidic diagnostic platforms. Their resistance to heat and pH extremes enables deployment in point-of-care settings in resource-limited environments — a multi-billion-dollar market opportunity.
Artificial intelligence is transforming nanobody design. Deep learning models trained on camelid VHH sequence-structure databases now enable in silico prediction of CDR conformations, epitope docking, and affinity optimization — dramatically reducing the experimental iteration cycle. Alpha Lifetech integrates AI-guided design with wet-lab validation for accelerated hit-to-lead timelines.
Unlike conventional IgG antibodies requiring mammalian cell culture, nanobodies can be produced at industrial scale in microbial systems (E. coli, Pichia pastoris) with yields of grams per liter. This dramatically reduces COGS (cost of goods sold), making llama-derived nanobodies highly attractive for both therapeutic and industrial enzyme/biosensor applications at commercial scale.
The outsourcing of nanobody discovery to specialized CROs has grown significantly, with Asia-Pacific CROs — particularly in China — capturing an increasing share of global projects due to competitive pricing, regulatory expertise, and integrated service offerings. Alpha Lifetech serves 800+ global clients across North America, Europe, and Asia with end-to-end nanobody development solutions.
Nanobodies are uniquely powerful tools for stabilizing GPCRs and other membrane proteins in specific conformational states, enabling cryo-EM and X-ray crystallography studies that were previously intractable. Llama immunization with detergent-purified or nanodisc-embedded membrane proteins generates conformation-selective nanobodies that act as molecular chaperones — unlocking structural insights for drug discovery against previously "undruggable" targets.
VHH nanobodies derived from llama immunization are being engineered as antigen-recognition domains in next-generation CAR-T cell therapies. Their compact size allows multi-specific CAR constructs targeting two or more tumor antigens simultaneously, reducing antigen escape — a major limitation of current CAR-T approaches. Several llama VHH-based CAR-T programs are advancing through IND-enabling studies.
Unlike conventional antibodies, nanobodies can be expressed intracellularly as "intrabodies" to modulate protein function within living cells. Llama immunization against cytoplasmic targets — transcription factors, kinases, oncoproteins — generates VHH intrabodies capable of inhibiting protein-protein interactions, degrading targets via PROTAC strategies, or acting as biosensors for real-time intracellular imaging.
Nanobodies' rapid tumor penetration and fast blood clearance make them ideal vectors for PET/SPECT imaging agents and targeted radionuclide therapy. Llama-immunization-derived anti-HER2, anti-EGFR, and anti-PSMA nanobodies labeled with 68Ga, 18F, or 177Lu are in clinical development, offering same-day imaging protocols impossible with full-size antibodies due to their slow pharmacokinetics.
Llama-derived nanobodies with high thermal and pH stability are being deployed in rapid test kits for food contaminant detection (mycotoxins, pesticide residues, veterinary drug residues) and environmental pollutant monitoring (heavy metals, endocrine disruptors). Their production in microbial systems enables low-cost, high-volume manufacturing for regulatory compliance testing across global food supply chains.
Nanobody-drug conjugates represent a next-generation ADC (antibody-drug conjugate) modality with superior tumor penetration and homogeneous drug-to-antibody ratios achievable through site-specific conjugation. Llama immunization provides the VHH targeting moiety, which is conjugated to cytotoxic payloads, photosensitizers, or immune cell engagers. Multiple NDC programs are in preclinical and early clinical development for solid tumors.
Our platform utilizes phage and yeast display technology to develop different forms of antibodies: VHH single domain antibodies, Fab antibodies, and scFv antibodies, resulting in high affinity and high specificity antibodies.
READ MORE
VHH Antibody Discovery Service
View Details
Fab Antibody Discovery Service
View Details
ScFv Antibody Discovery Service
View Details
Phage Display System
View Details
Phage Library Construction Service
View Details
Phage Display Screening Service
View DetailsThe aptamer platform provided by Alpha Lifetech includes two categories: aptamer synthesis platform, which mainly involves SELEX aptamer library synthesis service and aptamer development service, and aptamer screening platform including screening services based on SELEX technology for proteins, peptides, cells, small molecules, and other target molecules, as well as aptamer optimization and identification analysis services.
READ MORE
Aptamer Synthesis Platform
View Details
Aptamer Screening Platform
View Details
Aptamer Optimization Service
View Details
Aptamer Analysis Service
View Details
Aptamer Research Service
View Details
Our monoclonal antibody development services include three technologies: phage display technology, single-B cell technology, and hybridoma cell technology, which produce monoclonal antibodies for different species.
READ MORE
Single B Cell Sorting Platform
View Details
Hybridoma Technology Platform
View Details
Phage Display Technology Platform
View Details
Mouse mAb Development Service
View Details
Rabbit mAb Development Service
View DetailsWe also provide a series of technical services related to antibody engineering, stable cell line construction, yeast display, protein interaction analysis, etc., laying the foundation for antibody development.
READ MORE
Stable Cell Line Construction Service
View Details
Animal Immunization Platform
View Details
Protein Interaction Service
View Details
Yeast Display Library Construction Service
View Details
Yeast Display Library Screening Service
View DetailsExceptional Nanobody discovery capabilities from Alpha Lifetech. Their team's dedication to customer satisfaction and scientific excellence is evident in every interaction. Grateful for their partnership and looking forward to future collaborations!
Quality products! Our experience with Alpha Lifetech has been nothing short of outstanding.
Reliable, responsive, and results-driven — Alpha Lifetech.
Simply put, Alpha Lifetech delivers. Their dedication to customer satisfaction and quality service is unmatched, and we're grateful to have them as a trusted partner.
End-to-end llama immunization and VHH library construction for high-affinity nanobody generation against any target antigen.
High-throughput Fab antibody generation using phage display and yeast display platforms for diverse therapeutic applications.
Single-chain variable fragment discovery with optimized linker design for stability and functionality in diverse formats.
FACS-based single B cell isolation for direct cloning of antigen-specific antibody genes from immunized llamas and other species.
Optimized llama immunization protocols with antigen formulation, adjuvant selection, and immune response monitoring for superior nanobody library diversity.
Robust phage display screening of llama VHH libraries with multiple rounds of biopanning for high-affinity nanobody candidate selection.
SPR, BLI, and co-IP-based kinetic profiling of llama nanobody-antigen interactions for affinity and specificity characterization.
FACS-based yeast display screening for nanobody affinity maturation and engineering, complementing llama immunization-derived VHH discovery.